Your browser doesn't support javascript.
loading
Harnessing the power of IFN for therapeutic approaches to COVID-19.
Viox, Elise G; Bosinger, Steven E; Douek, Daniel C; Schreiber, Gideon; Paiardini, Mirko.
  • Viox EG; Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
  • Bosinger SE; Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
  • Douek DC; Emory NPRC Genomics Core Emory National Primate Research Center, Emory University, Atlanta, Georgia, USA.
  • Schreiber G; Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
  • Paiardini M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
J Virol ; 98(5): e0120423, 2024 May 14.
Article en En | MEDLINE | ID: mdl-38651899
ABSTRACT
Interferons (IFNs) are essential for defense against viral infections but also drive recruitment of inflammatory cells to sites of infection, a key feature of severe COVID-19. Here, we explore the complexity of the IFN response in COVID-19, examine the effects of manipulating IFN on SARS-CoV-2 viral replication and pathogenesis, and highlight pre-clinical and clinical studies evaluating the therapeutic efficacy of IFN in limiting COVID-19 severity.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Interferones / SARS-CoV-2 / COVID-19 / Tratamiento Farmacológico de COVID-19 Límite: Animals / Humans Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Interferones / SARS-CoV-2 / COVID-19 / Tratamiento Farmacológico de COVID-19 Límite: Animals / Humans Idioma: En Año: 2024 Tipo del documento: Article